Trials Today

There are approximately 5 volunteers who have specified "idiopathic pulmonary fibrosis" in their list of medical conditions. Join the ResearchMatch community today!

Search Results

26 studies

24 sponsors

1 condition

	Sponsor Condition of Interest
	Assessment of Continuous Positive Airway Pressure Therapy in IPF Columbia University Interstitial Lung Disease Obstructive Sleep Apnea The purpose of this study is to evaluate whether biomarkers of lung injury and remodeling are responsive to effective continuous positive airway pressure (CPAP) treatment in adults with idiopathic pulmonary fibrosis (IPF) and moderate-to-severe obstructive sleep apnea (OSA).... expand The purpose of this study is to evaluate whether biomarkers of lung injury and remodeling are responsive to effective continuous positive airway pressure (CPAP) treatment in adults with idiopathic pulmonary fibrosis (IPF) and moderate-to-severe obstructive sleep apnea (OSA). Type: Interventional Start Date: Jan 2023 open study
	A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis... Genentech, Inc. Idiopathic Pulmonary Fibrosis Systemic Sclerosis With Lung Involvement The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants... expand The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks. Type: Interventional Start Date: May 2023 open study
	Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough Mayo Clinic Interstitial Lung Disease This research study is evaluating the effectiveness of escalating doses of Amitriptyline and Duloxetine in reducing cough frequency in patients with interstitial lung disease (ILD)-related cough. expand This research study is evaluating the effectiveness of escalating doses of Amitriptyline and Duloxetine in reducing cough frequency in patients with interstitial lung disease (ILD)-related cough. Type: Interventional Start Date: Nov 2021 open study